Cargando…
Ferroptosis in Non-Small Cell Lung Cancer: Progression and Therapeutic Potential on It
As a main subtype of lung cancer, the current situation of non-small cell lung cancer (NSCLC) remains severe worldwide with a 19% survival rate at 5 years. As the conventional therapy approaches, such as chemotherapy, radiotherapy, targeted therapy, and immunotherapy, gradually develop into therapy...
Autores principales: | Zou, Jiayu, Wang, Li, Tang, Hailin, Liu, Xiuxiu, Peng, Fu, Peng, Cheng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8704137/ https://www.ncbi.nlm.nih.gov/pubmed/34948133 http://dx.doi.org/10.3390/ijms222413335 |
Ejemplares similares
-
Screening for Potential Therapeutic Agents for Non-Small Cell Lung Cancer by Targeting Ferroptosis
por: Zhao, Xin, et al.
Publicado: (2022) -
New Advances in the Research of Resistance to Neoadjuvant Chemotherapy in Breast Cancer
por: An, Junsha, et al.
Publicado: (2021) -
Compounds targeting ferroptosis in breast cancer: progress and their therapeutic potential
por: Xu, Chuchu, et al.
Publicado: (2023) -
Curcumin induces ferroptosis in non‐small‐cell lung cancer via activating autophagy
por: Tang, Xin, et al.
Publicado: (2021) -
Ferroptosis and triple-negative breast cancer: Potential therapeutic targets
por: Xu, Na, et al.
Publicado: (2022)